PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307750

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307750

Europe Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

PUBLISHED: June 1, 2023

PAGES: 181 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Europe pemphigus vulgaris market is expected to reach USD 166.32 million by 2030 from USD 92.68 million in 2022, growing at a CAGR of 7.7% during the forecast period of 2023 to 2030.

Market Segmentation:

Europe Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Overview of Europe Pemphigus Vulgaris Market Dynamics:

Driver
Rise in patients with rare diseases such as pemphigus vulgaris
Restraint
High cost of treatment
Opportunity
Rising healthcare facilities in the developing and underdeveloped countries

Market Players

The key market players operating in the market are:

F-Hoffmann La Roche Ltd.
Sanofi
Regeneron Pharmaceuticals Inc.
Fresenius Kabi AG
Novartis AG
Amgen Inc.
Merck & Co., Inc.
AstraZeneca
Teva Pharmaceutical Industries Ltd
Lilly
Zydus Group
GSK plc.

1 INTRODUCTION 18

1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 OVERVIEW 18
1.4 CURRENCY AND PRICING 20
1.5 LIMITATIONS 20
1.6 MARKETS COVERED 20

2 MARKET SEGMENTATION 23

2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.6 MULTIVARIATE MODELLING 30
2.7 MARKET APPLICATION COVERAGE GRID 31
2.8 PRODUCT LIFELINE CURVE 32
2.9 DBMR MARKET POSITION GRID 33
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35

3 EXECUTIVE SUMMARY 36

4 PREMIUM INSIGHTS 38

4.1 PESTEL ANALYSIS 39
4.2 PORTER FIVE FORCES 40
4.3 PATENT ANALYSIS 41
4.4 PATIENT FLOW DIAGRAM 42
4.5 KEY PRICING STRATEGIES 43
4.6 FUTURE THERAPIES 44
4.7 KEY PATIENT ENROLLMENT STRATEGIES 45

5 PIPELINE ANALYSIS 46

6 EPIDEMIOLOGY 47

7 INDUSTRY INSIGHTS 48

8 EUROPE PEMPHIGUS VULGARIS MARKET: REGULATIONS 49

9 MARKET OVERVIEW 52

9.1 DRIVERS 54
- 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 54
- 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 54
- 9.1.3 AWARENESS REGARDING THE DISEASE 55
9.2 RESTRAINTS 55
- 9.2.1 STRICT REGULATORY GUIDELINES 55
- 9.2.2 HIGH TREATMENT COSTS 55
9.3 OPPORTUNITIES 56
- 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 56
- 9.3.2 INCREASING HEALTHCARE FACILITIES 56
- 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 57
9.4 CHALLENGES 57
- 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 57
- 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 58

10 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 59

10.1 OVERVIEW 60
10.2 TREATMENT 63
- 10.2.1 MEDICATIONS, BY TYPE 63
  - 10.2.1.1 CORTICOSTEROIDS 64
  - 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 64
    - 10.2.1.2.1 AZATHIOPRINE 65
    - 10.2.1.2.2 MYCOPHENALATE MOFETIL 65
    - 10.2.1.2.3 METHOTREXATE 65
    - 10.2.1.2.4 CYCLOPHOSPHAMIDE 65
    - 10.2.1.2.5 MIZORIBINE 65
    - 10.2.1.2.6 OTHERS 65
  - 10.2.1.3 ANTI- INFLAMMATORY AGENTS 65
    - 10.2.1.3.1 DIAMINODYPHENYL SULFONE 66
    - 10.2.1.3.2 TETRACYCLINE 66
    - 10.2.1.3.3 OTHERS 66
  - 10.2.1.4 BIOLOGICS 66
  - 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 66
  - 10.2.1.6 ANTIBIOTICS 66
  - 10.2.1.7 ANTIFUNGALS 66
  - 10.2.1.8 ANTIVIRALS 66
  - 10.2.1.9 OTHER MEDICATIONS 66
- 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 66
  - 10.2.2.1 ORAL 67
  - 10.2.2.2 TOPICAL 67
  - 10.2.2.3 PARENTERAL 67
  - 10.2.2.4 OTHERS 67
- 10.2.3 MEDICATIONS, BY DRUG TYPE 67
  - 10.2.3.1 GENERIC 68
  - 10.2.3.2 BRANDED 68
10.3 DIAGNOSIS 68
- 10.3.1 SKIN BIOPSY 69
- 10.3.2 BLOOD TEST 69
- 10.3.3 ENDOSCOPY 69

11 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 70

11.1 OVERVIEW 71
11.2 ADULTS 74
11.3 GERIATRIC 75
11.4 PEDIATRIC 76

12 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 77

12.1 OVERVIEW 78
12.2 HOSPITALS 81
12.3 SPECIALTY CLINICS 81
12.4 RESEARCH INSTITUTES 82
12.5 OTHERS 83

13 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 84

13.1 OVERVIEW 85
13.2 HOSPITALS PHARMACY 88
13.3 RETAIL PHARMACY 88
13.4 ONLINE PHARMACY 89

14 EUROPE PEMPHIGUS VULGARIS MARKET, BY REGION 90

14.1 EUROPE 91
- 14.1.1 GERMANY 100
- 14.1.2 U.K. 104
- 14.1.3 FRANCE 108
- 14.1.4 ITALY 112
- 14.1.5 SPAIN 116
- 14.1.6 SWITZERLAND 120
- 14.1.7 TURKEY 124
- 14.1.8 RUSSIA 128
- 14.1.9 BELGIUM 132
- 14.1.10 NETHERLANDS 136
- 14.1.11 REST OF EUROPE 139

15 EUROPE PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 140

15.1 COMPANY SHARE ANALYSIS: EUROPE 140

16 SWOT ANALYSIS 141

17 COMPANY PROFILE 142

17.1 ABBVIE INC. 142
- 17.1.1 COMPANY SNAPSHOT 142
- 17.1.2 REVENUE ANALYSIS 142
- 17.1.3 COMPANY SHARE ANALYSIS 143
- 17.1.4 PRODUCT PORTFOLIO 143
- 17.1.5 RECENT DEVELOPMENTS 144
17.2 MERCK & CO., INC., 145
- 17.2.1 COMPANY SNAPSHOT 145
- 17.2.2 REVENUE ANALYSIS 145
- 17.2.3 COMPANY SHARE ANALYSIS 146
- 17.2.4 PRODUCT PORTFOLIO 146
- 17.2.5 RECENT DEVELOPMENT 146
17.3 SANOFI 147
- 17.3.1 COMPANY SNAPSHOT 147
- 17.3.2 REVENUE ANALYSIS 147
- 17.3.3 COMPANY SHARE ANALYSIS 148
- 17.3.4 PRODUCT PORTFOLIO 148
- 17.3.5 RECENT DEVELOPMENT 148
17.4 REGENERON PHARMACEUTICALS INC. 149
- 17.4.1 COMPANY SNAPSHOT 149
- 17.4.2 REVENUE ANALYSIS 149
- 17.4.3 COMPANY SHARE ANALYSIS 150
- 17.4.4 PRODUCT PORTFOLIO 150
- 17.4.5 RECENT DEVELOPMENT 150
17.5 NOVARTIS AG 151
- 17.5.1 COMPANY SNAPSHOT 151
- 17.5.2 REVENUE ANALYSIS 151
- 17.5.3 COMPANY SHARE ANALYSIS 152
- 17.5.4 PRODUCT PORTFOLIO 152
- 17.5.5 RECENT DEVELOPMENT 152
17.6 AMGEN INC. 153
- 17.6.1 COMPANY SNAPSHOT 153
- 17.6.2 REVENUE ANALYSIS 153
- 17.6.3 PRODUCT PORTFOLIO 154
- 17.6.4 RECENT DEVELOPMENTS 154
17.7 ASTRAZENECA 155
- 17.7.1 COMPANY SNAPSHOT 155
- 17.7.2 REVENUE ANALYSIS 155
- 17.7.3 COMPANY SHARE ANALYSIS 156
- 17.7.4 PRODUCT PORTFOLIO 156
- 17.7.5 RECENT DEVELOPMENTS 157
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 158
- 17.8.1 COMPANY SNAPSHOT 158
- 17.8.2 REVENUE ANALYSIS 158
- 17.8.3 PRODUCT PORTFOLIO 159
- 17.8.4 RECENT DEVELOPMENT 159
17.9 CELLTRION HEALTHCARE CO., LTD 160
- 17.9.1 COMPANY SNAPSHOT 160
- 17.9.2 REVENUE ANALYSIS 160
- 17.9.3 PRODUCT PORTFOLIO 161
- 17.9.4 RECENT DEVELOPMENTS 161
17.10 F. HOFFMANN- LA ROCHE LTD. 162
- 17.10.1 COMPANY SNAPSHOT 162
- 17.10.2 REVENUE ANALYSIS 162
- 17.10.3 PRODUCT PORTFOLIO 163
- 17.10.4 RECENT DEVELOPMENT 163
17.11 FRESENIUS KABI AG 164
- 17.11.1 COMPANY SNAPSHOT 164
- 17.11.2 REVENUE ANALYSIS 164
- 17.11.3 PRODUCT PORTFOLIO 165
- 17.11.4 RECENT DEVELOPMENT 165
17.12 GSK PLC 166
- 17.12.1 COMPANY SNAPSHOT 166
- 17.12.2 REVENUE ANALYSIS 166
- 17.12.3 PRODUCT PORTFOLIO 167
- 17.12.4 RECENT DEVELOPMENT 167
17.13 JOHNSON & JOHNSON SERVICES, INC. 168
- 17.13.1 COMPANY SNAPSHOT 168
- 17.13.2 REVENUE ANALYSIS 168
- 17.13.3 COMPANY SHARE ANALYSIS 169
- 17.13.4 PRODUCT PORTFOLIO 169
- 17.13.5 RECENT DEVELOPMENT 169
17.14 LILLY 170
- 17.14.1 COMPANY SNAPSHOT 170
- 17.14.2 REVENUE ANALYSIS 170
- 17.14.3 PRODUCT PORTFOLIO 171
- 17.14.4 RECENT DEVELOPMENT 171
17.15 PFIZER INC. 172
- 17.15.1 COMPANY SNAPSHOT 172
- 17.15.2 REVENUE ANALYSIS 172
- 17.15.3 PRODUCT PORTFOLIO 173
- 17.15.4 RECENT DEVELOPMENT 173
17.16 RAKSHIT DRUGS PVT. LTD 174
- 17.16.1 COMPANY SNAPSHOT 174
- 17.16.2 PRODUCT PORTFOLIO 174
- 17.16.3 RECENT DEVELOPMENT 174
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 175
- 17.17.1 COMPANY SNAPSHOT 175
- 17.17.2 REVENUE ANALYSIS 175
- 17.17.3 PRODUCT PORTFOLIO 176
- 17.17.4 RECENT DEVELOPMENT 176
17.18 ZYDUS GROUP 177
- 17.18.1 COMPANY SNAPSHOT 177
- 17.18.2 REVENUE ANALYSIS 177
- 17.18.3 PRODUCT PORTFOLIO 178
- 17.18.4 RECENT DEVELOPMENT 178

18 QUESTIONNAIRE 179

19 RELATED REPORTS 181

LIST OF TABLES

TABLE 1 EUROPE PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 41
TABLE 2 EUROPE PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 46
TABLE 3 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 62
TABLE 4 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 63
TABLE 5 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 64
TABLE 6 EUROPE STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 64
TABLE 7 EUROPE ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
TABLE 8 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 67
TABLE 9 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 67
TABLE 10 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 11 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 69
TABLE 12 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 73
TABLE 13 EUROPE ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 14 EUROPE GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 15 EUROPE PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 16 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 80
TABLE 17 EUROPE HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 18 EUROPE SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 19 EUROPE RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 20 EUROPE OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 21 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 87
TABLE 22 EUROPE HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 23 EUROPE RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 24 EUROPE ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 25 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 95
TABLE 26 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 95
TABLE 27 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 96
TABLE 28 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 96
TABLE 29 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
TABLE 30 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 97
TABLE 31 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 97
TABLE 32 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
TABLE 33 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 98
TABLE 34 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 98
TABLE 35 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 99
TABLE 36 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 100
TABLE 37 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 100
TABLE 38 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
TABLE 39 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
TABLE 40 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 101
TABLE 41 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 102
TABLE 42 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
TABLE 43 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 102
TABLE 44 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 45 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 103
TABLE 46 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 104
TABLE 47 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 104
TABLE 48 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 49 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 50 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 105
TABLE 51 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 106
TABLE 52 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 53 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 106
TABLE 54 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
TABLE 55 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 107
TABLE 56 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 108
TABLE 57 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 108
TABLE 58 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
TABLE 59 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
TABLE 60 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 109
TABLE 61 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 110
TABLE 62 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
TABLE 63 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 110
TABLE 64 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 110
TABLE 65 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 111
TABLE 66 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 112
TABLE 67 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
TABLE 68 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
TABLE 69 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
TABLE 70 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 113
TABLE 71 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 114
TABLE 72 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
TABLE 73 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 114
TABLE 74 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 114
TABLE 75 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115
TABLE 76 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 116
TABLE 77 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
TABLE 78 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 79 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 80 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 117
TABLE 81 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 118
TABLE 82 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 83 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 118
TABLE 84 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 118
TABLE 85 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
TABLE 86 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 120
TABLE 87 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
TABLE 88 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
TABLE 89 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
TABLE 90 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 121
TABLE 91 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 121
TABLE 92 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 93 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 122
TABLE 94 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
TABLE 95 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 123
TABLE 96 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 124
TABLE 97 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
TABLE 98 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
TABLE 99 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
TABLE 100 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 125
TABLE 101 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 126
TABLE 102 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
TABLE 103 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 126
TABLE 104 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
TABLE 105 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 127
TABLE 106 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 128
TABLE 107 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 108 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 109 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 110 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 129
TABLE 111 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 130
TABLE 112 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
TABLE 113 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 130
TABLE 114 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 115 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
TABLE 116 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 132
TABLE 117 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 118 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 119 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 120 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 133
TABLE 121 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 134
TABLE 122 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
TABLE 123 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 134
TABLE 124 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 134
TABLE 125 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 135
TABLE 126 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 136
TABLE 127 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 136
TABLE 128 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 129 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 130 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 137
TABLE 131 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 137
TABLE 132 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
TABLE 133 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 138
TABLE 134 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 138
TABLE 135 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
TABLE 136 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 139

LIST OF FIGURES

FIGURE 1 EUROPE PEMPHIGUS VULGARIS MARKET: SEGMENTATION 23
FIGURE 2 EUROPE PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 26
FIGURE 3 EUROPE PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 27
FIGURE 4 EUROPE PEMPHIGUS VULGARIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 EUROPE PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 EUROPE PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 31
FIGURE 8 EUROPE PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 33
FIGURE 9 EUROPE PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 34
FIGURE 10 EUROPE PEMPHIGUS VULGARIS MARKET: SEGMENTATION 37
FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 38
FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 38
FIGURE 13 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 42
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE PEMPHIGUS VULGARIS MARKET 53
FIGURE 15 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 60
FIGURE 16 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 61
FIGURE 17 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 61
FIGURE 18 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 62
FIGURE 19 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 71
FIGURE 20 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 72
FIGURE 21 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 72
FIGURE 22 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 73
FIGURE 23 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 78
FIGURE 24 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 79
FIGURE 25 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 79
FIGURE 26 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 80
FIGURE 27 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 85
FIGURE 28 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 86
FIGURE 29 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 86
FIGURE 30 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 87
FIGURE 31 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 92
FIGURE 32 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 93
FIGURE 33 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 93
FIGURE 34 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 94
FIGURE 35 EUROPE PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 94
FIGURE 36 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 140

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ